MNG1055
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.436
- PROTEIN_SECRETION+0.364
- MYC_TARGETS_V1+0.359
- MYC_TARGETS_V2+0.298
- OXIDATIVE_PHOSPHORYLATION+0.260
- DNA_REPAIR+0.244
- HYPOXIA+0.234
- GLYCOLYSIS+0.212
- MTORC1_SIGNALING+0.190
- CHOLESTEROL_HOMEOSTASIS+0.187
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.462
- ALLOGRAFT_REJECTION-0.451
- INTERFERON_ALPHA_RESPONSE-0.424
- IL6_JAK_STAT3_SIGNALING-0.336
- INFLAMMATORY_RESPONSE-0.244
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.243
- COMPLEMENT-0.241
- MYOGENESIS-0.239
- KRAS_SIGNALING_UP-0.238
- APICAL_SURFACE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303753 | — | — | 0.848 |
| 2 | SRR650181 | — | — | 0.829 |
| 3 | TCGA-IQ-A6SG-01A-12R-A34R-07 | — | — | 0.817 |
| 4 | MNG962 | — | — | 0.815 |
| 5 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.814 |
| 6 | R205 | — | — | 0.814 |
| 7 | MNG460 | — | — | 0.808 |
| 8 | SRR6013533 | — | cohortSQ2 | 0.808 |
| 9 | SRR10900581 | — | — | 0.805 |
| 10 | MNG666 | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.436 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.364 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.359 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.298 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.244 | Idelalisib | — uncovered |
| HYPOXIA | 0.234 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.212 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.187 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.157 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.156 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.153 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.135 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.133 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.133 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.119 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.094 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.085 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.082 | Idelalisib | — uncovered |